256 results on '"Reddy, Manjula"'
Search Results
2. Cleavage of Braun’s lipoprotein Lpp from the bacterial peptidoglycan by a paralog of L,D-transpeptidases, LdtF
3. NEMO: Improved and accurate models for identification of 6mA using Nanopore sequencing
4. Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease
5. Glycan strand cleavage by a lytic transglycosylase, MltD contributes to the expansion of peptidoglycan in Escherichia coli
6. Crosslink cleaving enzymes: the smart autolysins that remodel the bacterial cell wall
7. Peptidoglycan hydrolase of an unusual cross-link cleavage specificity contributes to bacterial cell wall synthesis
8. Cross-talk between phospholipid synthesis and peptidoglycan expansion by a cell wall hydrolase
9. Application of Cell-Based Assays in Clinical Trials
10. Glycan strand cleavage by a lytic transglycosylase, MltD contributes to the expansion of peptidoglycan in Escherichia coli
11. Supplementary Figure 1 from A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors
12. Figure S1 from A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease
13. Supplementary Methods, Table 1 from A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors
14. Supplementary Methods from A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease
15. Supplementary Table S1 from A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease
16. Peptidoglycan Remodeling by an L,D-Transpeptidase, LdtD during Cold Shock in Escherichia coli
17. Regulated proteolysis of a cross-link–specific peptidoglycan hydrolase contributes to bacterial morphogenesis
18. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial
19. Enumeration and characterization of circulating multiple myeloma cells in patients with plasma cell disorders
20. A LytM-Domain Factor, ActS, Functions in Two Distinctive Peptidoglycan Hydrolytic Pathways in E. coli
21. Identification of YfiH (PgeF) as a factor contributing to the maintenance of bacterial peptidoglycan composition
22. Dose selection of siltuximab for multicentric Castleman’s disease
23. Modulation of RecFORQ- and RecA-Mediated Homologous Recombination in Escherichia coli by Isoforms of Translation Initiation Factor IF2
24. Application of Cell-Based Assays in Clinical Trials
25. Analysis of CD28 Interactions with Its Cognate Counter-Receptors CD80 and CD86
26. Structural Basis for the Peptidoglycan-Editing Activity of YfiH
27. Peptidoglycan: Structure, Synthesis, and Regulation
28. Development and validation of panoptic Meso scale discovery assay to quantify total systemic interleukin-6
29. A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma
30. A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer
31. Three Isoforms of the Essential Translation Initiation Factor IF2 Differentially Modulate Homologous Recombination in Escherichia coli
32. Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma
33. A phase 2, randomized, double-blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low- or intermediate-1–risk myelodysplastic syndrome
34. yciM is an essential gene required for regulation of lipopolysaccharide synthesis in Escherichia coli
35. Cleavage of Braun’s lipoprotein Lpp from the bacterial peptidoglycan by a paralog ofl,d-transpeptidases, LdtF
36. Role of sufI (FtsP) in cell division of Escherichia coli: evidence for its involvement in stabilizing the assembly of the divisome
37. Role of FtsEX in cell division of Escherichia coli: viability of ftsEX mutants is dependent on functional SufI or high osmotic strength
38. Cleavage of Braun lipoprotein Lpp from the bacterial peptidoglycan by a paralog of L,D-transpeptidases, LdtF
39. Distinct signatures for mutator sensitivity of lacZ reversions and for the spectrum of lacI/lacO forward mutations on the chromosome of nondividing Escherichia coli
40. Three redundant murein endopeptidases catalyse an essential cleavage step in peptidoglycan synthesis of Escherichia coli K12
41. Introduction to Biomarkers
42. Regulatory Compliance and Method Validation
43. Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma
44. IS186 insertion at a hot spot in the lon promoter as a basis for lon protease deficiency of Escherichia coli B: identification of a consensus target sequence for IS186 transposition
45. The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study
46. Lon incompatibility associated with mutations causing SOS induction: null uvrD alleles induce an SOS response in Escherichia coli
47. Characterization of the uup locus and its role in transposon excisions and tandem repeat deletions in Escherichia coli
48. Positive treatment effects of ustekinumab in psoriasis: Analysis of lesional and systemic parameters
49. Reply to Hong et al.: Synthetic lethality of fabH nlpI double mutant of E. coli is not contingent upon osmotic strength of the medium.
50. A genetic strategy to demonstrate the occurrence of spontaneous mutations in nondividing cells within colonies of Escherichia coli
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.